EUVIMEDEUVIMED entdecken
Crossref

What are the benefits and harms of immune checkpoint inhibitors (ICIs) in adults aged ≥ 65 years with early-stage resectable non-small cell lung cancer (NSCLC)?

Kwun M Fong

Cochrane Clinical Answers · 09.11.2026

DOI: 10.1002/cca.4861 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cochrane Clinical Answers, online erschienen am 09.11.2026. Verfasst von Kwun M Fong. Die Arbeit nennt 7 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Fong, K. M. (2026). What are the benefits and harms of immune checkpoint inhibitors (ICIs) in adults aged ≥ 65 years with early-stage resectable non-small cell lung cancer (NSCLC)?. Cochrane Clinical Answers. https://doi.org/10.1002/cca.4861

Vancouver

Fong KM. What are the benefits and harms of immune checkpoint inhibitors (ICIs) in adults aged ≥ 65 years with early-stage resectable non-small cell lung cancer (NSCLC)?. Cochrane Clinical Answers. 2026. doi:10.1002/cca.4861

BibTeX
@article{Fong2026,
  author = {Fong, Kwun M},
  title = {What are the benefits and harms of immune checkpoint inhibitors (ICIs) in adults aged ≥ 65 years with early-stage resectable non-small cell lung cancer (NSCLC)?},
  journal = {Cochrane Clinical Answers},
  year = {2026},
  doi = {10.1002/cca.4861}
}
Kostenlos starten →